TGFB1 and cirrhosis of liver: In this study, 48 weeks of telbivudine therapy rather than entecavir therapy was found to be associated with TGF-β1 hyperactivity, IgG-related hypergammaglobulinemia, and a decrease in the proportion of serum IgG-Fc galactosylation in the patients with HBV-related liver cirrhosis.